{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:16:24Z","timestamp":1789755384529,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1053\/j.ajkd.2026.03.036","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T03:45:20Z","timestamp":1778125520000},"page":"1-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["KDOQI US Commentary on the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in CKD"],"prefix":"10.1053","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1975-8650","authenticated-orcid":false,"given":"Diana I.","family":"Jalal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique E.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fishbane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando M.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba P.","family":"Kovesdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Kshirsagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Spinowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Wish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1053\/j.ajkd.2026.03.036_bib1","first-page":"S1","article-title":"KDIGO 2026 clinical practice guideline for the management of anemia in chronic kidney disease (CKD)","volume":"109","year":"2026","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2026.03.036_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100677","article-title":"Iron-deficiency anemia in CKD: a narrative review for the kidney care team","volume":"5","author":"Hain","year":"2023","journal-title":"Kidney Med"},{"issue":"9","key":"10.1053\/j.ajkd.2026.03.036_bib3","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1681\/ASN.2015050535","article-title":"The risk of major hemorrhage with CKD","volume":"27","author":"Molnar","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2026.03.036_bib4","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2215\/CJN.02170216","article-title":"Chronic kidney disease and risk for gastrointestinal bleeding in the community: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"11","author":"Ishigami","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2026.03.036_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000037274","article-title":"Gastrointestinal bleeding among 151 patients undergoing maintenance hemodialysis for end-stage renal failure: a 5-year follow-up study","volume":"103","author":"Nakayama","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1053\/j.ajkd.2026.03.036_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12937-025-01072-1","article-title":"Association of iron deficiency with kidney outcome and all-cause mortality in chronic kidney disease patients without anemia","volume":"24","author":"Yu","year":"2025","journal-title":"Nutr J"},{"issue":"11","key":"10.1053\/j.ajkd.2026.03.036_bib7","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1016\/j.ekir.2021.07.032","article-title":"Iron deficiency in CKD without concomitant anemia","volume":"6","author":"Wish","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1053\/j.ajkd.2026.03.036_bib8","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fphys.2019.00304","article-title":"The EPO-FGF23 signaling pathway in erythroid progenitor cells: opening a new area of research","volume":"10","author":"Van Vuren","year":"2019","journal-title":"Front Physiol"},{"issue":"3","key":"10.1053\/j.ajkd.2026.03.036_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/ejendo\/lvaf039","article-title":"Primary hyperparathyroidism induces erythropoietin resistance through fibroblast growth factor 23","volume":"192","author":"Huber","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1053\/j.ajkd.2026.03.036_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12882-018-1021-3","article-title":"Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease","volume":"19","author":"Eisenga","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1053\/j.ajkd.2026.03.036_bib11","series-title":"Prescribing information: Auryxia (ferric citrate) tablets, for oral use","year":"2024"},{"issue":"2","key":"10.1053\/j.ajkd.2026.03.036_bib12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1681\/ASN.2014020212","article-title":"Ferric citrate controls phosphorus and delivers iron in patients on dialysis","volume":"26","author":"Lewis","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2026.03.036_bib13","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1681\/ASN.2014080842","article-title":"Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD","volume":"26","author":"Umanath","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2026.03.036_bib14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2026.03.036_bib15","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1093\/ndt\/gfy190","article-title":"Association between serum ferritin and mortality: findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study","volume":"33","author":"Karaboyas","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2026.03.036_bib16","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2215\/CJN.03970318","article-title":"Safety of dynamic intravenous iron administration strategies in hemodialysis patients","volume":"14","author":"Li","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2026.03.036_bib17","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1681\/ASN.2006091034","article-title":"Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients\u2019 Response to IV Iron with Elevated Ferritin (DRIVE) Study","volume":"18","author":"Coyne","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"4 suppl 3","key":"10.1053\/j.ajkd.2026.03.036_bib18","first-page":"S192","article-title":"NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative","volume":"30","year":"1997","journal-title":"Am J Kidney Dis"},{"issue":"5 suppl 3","key":"10.1053\/j.ajkd.2026.03.036_bib19","first-page":"S16","article-title":"KDOQI; National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults","volume":"47","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2026.03.036_bib20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis","volume":"68","author":"Shepshelovich","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2026.03.036_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116202","article-title":"Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management","volume":"154","author":"Schaefer","year":"2022","journal-title":"Bone"},{"issue":"11","key":"10.1053\/j.ajkd.2026.03.036_bib22","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.3390\/jcm9113587","article-title":"A pooled analysis of serum phosphate measurements and potential hypophosphataemia events in 45 interventional trials with ferric carboxymaltose","volume":"9","author":"Rosano","year":"2020","journal-title":"J Clin Med"},{"issue":"5","key":"10.1053\/j.ajkd.2026.03.036_bib23","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/bcp.14643","article-title":"Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside\u2014a systematic review and meta-analysis","volume":"87","author":"Schaefer","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1053\/j.ajkd.2026.03.036_bib24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ajh.27598","article-title":"Ferric carboxymaltose (FCM)-associated hypophosphatemia (HPP): a systematic review","volume":"100","author":"Magagnoli","year":"2025","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1053\/j.ajkd.2026.03.036_bib25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2026.03.036_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/468675","article-title":"Intravenous iron administration and hypophosphatemia in clinical practice","volume":"2015","author":"Hardy","year":"2015","journal-title":"Int J Rheumatol"},{"issue":"5","key":"10.1053\/j.ajkd.2026.03.036_bib27","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/jgh3.12150","article-title":"Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose","volume":"3","author":"Fang","year":"2019","journal-title":"JGH Open"},{"issue":"7","key":"10.1053\/j.ajkd.2026.03.036_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/qjmed\/hcq039","article-title":"Medication-induced hypophosphatemia: a review","volume":"103","author":"Liamis","year":"2010","journal-title":"QJM"},{"issue":"14","key":"10.1053\/j.ajkd.2026.03.036_bib29","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.3390\/jcm14144861","article-title":"Evaluating the risk of hypophosphatemia with ferric carboxymaltose and the recommended approaches for management: a consensus statement","volume":"14","author":"Rosano","year":"2025","journal-title":"J Clin Med"},{"issue":"7257","key":"10.1053\/j.ajkd.2026.03.036_bib30","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/nature08301","article-title":"Function and biogenesis of iron-sulphur proteins","volume":"460","author":"Lill","year":"2009","journal-title":"Nature"},{"issue":"2","key":"10.1053\/j.ajkd.2026.03.036_bib31","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.cmet.2010.06.007","article-title":"Iron regulatory proteins secure mitochondrial iron sufficiency and function","volume":"12","author":"Galy","year":"2010","journal-title":"Cell Metab"},{"issue":"6","key":"10.1053\/j.ajkd.2026.03.036_bib32","doi-asserted-by":"crossref","first-page":"E535","DOI":"10.1152\/ajpendo.1984.246.6.E535","article-title":"Distinguishing effects of anemia and muscle iron deficiency on exercise bioenergetics in the rat","volume":"246","author":"Davies","year":"1984","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"10.1053\/j.ajkd.2026.03.036_bib33","first-page":"E418","article-title":"Muscle mitochondrial bioenergetics, oxygen supply, and work capacity during dietary iron deficiency and repletion","volume":"242","author":"Davies","year":"1982","journal-title":"Am J Physiol"},{"issue":"6","key":"10.1053\/j.ajkd.2026.03.036_bib34","first-page":"427","article-title":"Skeletal muscle mitophagy in chronic disease: implications for muscle oxidative capacity?","volume":"19","author":"Leermakers","year":"2016","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"3","key":"10.1053\/j.ajkd.2026.03.036_bib35","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.celrep.2015.09.023","article-title":"Lethal cardiomyopathy in mice lacking transferrin receptor in the heart","volume":"13","author":"Xu","year":"2015","journal-title":"Cell Rep"},{"issue":"25","key":"10.1053\/j.ajkd.2026.03.036_bib36","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"issue":"10266","key":"10.1053\/j.ajkd.2026.03.036_bib37","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.ajkd.2026.03.036_bib38","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2215\/CJN.15360920","article-title":"Heart failure hospitalization risk associated with iron status in veterans with CKD","volume":"16","author":"Cho","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2026.03.036_bib39","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41430-020-00742-z","article-title":"Iron deficiency, fatigue and muscle strength and function in older hospitalized patients","volume":"75","author":"Neidlein","year":"2021","journal-title":"Eur J Clin Nutr"},{"issue":"17","key":"10.1053\/j.ajkd.2026.03.036_bib40","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"10.1053\/j.ajkd.2026.03.036_bib41","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1053\/j.ajkd.2026.03.036_bib42","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1159\/000528443","article-title":"Overall adverse event profile of vadadustat versus darbepoetin alfa for the treatment of anemia associated with chronic kidney disease in phase 3 trials","volume":"53","author":"Agarwal","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2026.03.036_bib43","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1681\/ASN.0000000708","article-title":"Safety and efficacy of vadadustat for the treatment of CKD-related anemia within and outside the United States","volume":"36","author":"Chertow","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2026.03.036_bib44","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2025.2491655","article-title":"HIF-PHIs associated with embolic and thrombotic events: a real-world pharmacovigilance study based on the Japan Adverse Drug Event Report database","volume":"47","author":"Wu","year":"2025","journal-title":"Ren Fail"},{"key":"10.1053\/j.ajkd.2026.03.036_bib45","series-title":"Prescribing information: Epogen (epoetin alfa) injection, for intravenous or subcutaneous use","year":"2024"},{"issue":"21","key":"10.1053\/j.ajkd.2026.03.036_bib46","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.ajkd.2026.03.036_bib47","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2026.03.036_bib48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0272-6386(95)90654-1","article-title":"Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients","volume":"26","author":"Paganini","year":"1995","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1053\/j.ajkd.2026.03.036_bib49","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1056\/NEJM199808273390902","article-title":"Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients","volume":"339","author":"Kaufman","year":"1998","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2026.03.036_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/S0272-6386(05)90000-0","article-title":"Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: results from the 1998 End-Stage Renal Disease Core Indicators Project","volume":"37","author":"McClellan","year":"2001","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2026.03.036_bib51","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0272-6386(99)70258-1","article-title":"Neocytolysis contributes to the anemia of renal disease","volume":"33","author":"Rice","year":"1999","journal-title":"Am J Kidney Dis"},{"issue":"20","key":"10.1053\/j.ajkd.2026.03.036_bib52","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2026.03.036_bib53","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2026.03.036_bib54","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.ajkd.2024.09.006","article-title":"Vadadustat three times weekly in patients with anemia due to dialysis-dependent CKD","volume":"85","author":"Toka","year":"2025","journal-title":"Am J Kidney Dis"},{"issue":"17","key":"10.1053\/j.ajkd.2026.03.036_bib55","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2026.03.036_bib56","series-title":"Prescribing information: Vafseo (vadadustat) tablets, for oral use","year":"2024"},{"issue":"5","key":"10.1053\/j.ajkd.2026.03.036_bib57","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/ckj\/sfac271","article-title":"The impacts of hypoxia-inducible factor stabilizers on laboratory parameters and clinical outcomes in chronic kidney disease patients with renal anemia: a systematic review and meta-analysis","volume":"16","author":"Takkavatakarn","year":"2023","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1053\/j.ajkd.2026.03.036_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfad143","article-title":"Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials","volume":"17","author":"Minutolo","year":"2024","journal-title":"Clin Kidney J"},{"issue":"6","key":"10.1053\/j.ajkd.2026.03.036_bib59","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.18632\/aging.204611","article-title":"A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease","volume":"15","author":"Chen","year":"2023","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"10.1053\/j.ajkd.2026.03.036_bib60","doi-asserted-by":"crossref","first-page":"198","DOI":"10.25259\/ijn_379_23","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in dialysis-dependent chronic kidney disease: systematic review and meta-analysis of randomized controlled trials","volume":"35","author":"Tyagi","year":"2025","journal-title":"Indian J Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2026.03.036_bib61","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2010.10.007","article-title":"US Renal Data System 2010 annual data report","volume":"57","author":"Collins","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"4S1","key":"10.1053\/j.ajkd.2026.03.036_bib62","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1053\/j.ajkd.2024.01.001","article-title":"US Renal Data System 2023 annual data report: epidemiology of kidney disease in the United States","volume":"83","author":"Johansen","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2026.03.036_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/frtra.2023.1215130","article-title":"Clinical impact of early post-transplant red cell transfusions in kidney transplantation: a systematic review and meta-analysis","volume":"2","author":"Hassan","year":"2023","journal-title":"Front Transplant"},{"key":"10.1053\/j.ajkd.2026.03.036_bib64","article-title":"Organ Procurement and Transplantation Network (OPTN). The new Kidney Allocation System (KAS)","year":"2014","journal-title":"Organ Procurement and Transplantation Network (OPTN)"},{"issue":"2","key":"10.1053\/j.ajkd.2026.03.036_bib65","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40620-019-00680-5","article-title":"Red cell transfusion in chronic kidney disease in the United States in the current era of erythropoiesis stimulating agents","volume":"33","author":"Brenner","year":"2020","journal-title":"J Nephrol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626008413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626008413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:29:16Z","timestamp":1782512956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638626008413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0272638626008413"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.03.036","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KDOQI US Commentary on the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in CKD","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.03.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}